Evaluation of the Paradoxical Association Between Lipid Levels and Incident Atrial Fibrillation According to Statin Usage: A Nationwide Cohort Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Higher levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are associated with a lower risk of atrial fibrillation (AF). Statin use might exert confounding effects on the paradoxical associations; however, the relationships that distinguish statin users from non-users have not been thoroughly evaluated. Methods: From the Korean National Health Insurance Database, we included 9,778,014 adults who underwent a health examination in 2009. The levels of TC and LDL-C at the health examination were categorized into quartile values of the total study population. We grouped the study population into statin users and non-users and investigated the associations between TC, LDL-C, and the risk of incident AF. Results: Of the total population, 867,336 (8.9%) were taking statins. During a mean follow-up of 8.2 years, inverse associations of TC – AF and LDL-C – AF were observed; higher levels of TC and LDL-C were associated with the lower risk of AF in the total population. Overall, statin users showed higher AF incidence rate than non-users, but the inverse associations of TC – AF and LDL-C – AF were consistently observed irrespective of statin usage; adjusted hazard ratio with 95% confidence interval was 0.81 (0.79–0.84) for statin users and 0.81 (0.80–0.83) for non-users in the highest TC quartile, and 0.84 (0.82–0.87) for statin users and 0.85 (0.84–0.86) for non-users in the highest LDL-C quartile (all p<0.001). Conclusion: The paradoxical relationship between lipid levels (TC and LDL-C) and the risk of AF remains consistent in both statin users and non-users.
Abstract
Objective: Higher levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are associated with a lower risk of atrial fibrillation (AF). Statin use might exert confounding effects on the paradoxical associations; however, the relationships that distinguish statin users from non-users have not been thoroughly evaluated. Methods: From the Korean National Health Insurance Database, we included 9,778,014 adults who underwent a health examination in 2009. The levels of TC and LDL-C at the health examination were categorized into quartile values of the total study population. We grouped the study population into statin users and non-users and investigated the associations between TC, LDL-C, and the risk of incident AF. Results: Of the total population, 867,336 (8.9%) were taking statins. During a mean follow-up of 8.2 years, inverse associations of TC – AF and LDL-C – AF were observed; higher levels of TC and LDL-C were associated with the lower risk of AF in the total population. Overall, statin users showed higher AF incidence rate than non-users, but the inverse associations of TC – AF and LDL-C – AF were consistently observed irrespective of statin usage; adjusted hazard ratio with 95% confidence interval was 0.81 (0.79–0.84) for statin users and 0.81 (0.80–0.83) for non-users in the highest TC quartile, and 0.84 (0.82–0.87) for statin users and 0.85 (0.84–0.86) for non-users in the highest LDL-C quartile (all p<0.001). Conclusion: The paradoxical relationship between lipid levels (TC and LDL-C) and the risk of AF remains consistent in both statin users and non-users.
참고문헌 (48)
- Staerk L, "Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study", BMJ, 361, pp.k1453~ (2018)
- Zhang J, "Epidemiology of atrial fibrillation : geographic", ecological risk factors, age, sex, genetics, 2021, pp.13, 1~23
- Ruddox V, "Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure : a systematic review and meta-analysis", Eur J Prev Cardiol, 24, pp.1555~1566 (2017)
- Burdett P, "Atrial fibrillation in the UK : predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs", Eur Heart J Qual Care Clin Outcomes, 8, pp.187~194 (2022)
- Potpara TS, "The 4S-AF scheme(stroke risk; symptoms; severity of burden; substrate) : a novel approach to in-depth characterization(rather than classification)of atrial fibrillation", Thromb Haemost, 121, pp.270~278 (2021)
- Hindricks G, "2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC", Eur Heart J, 42, pp.373~498 (2021)
- Chao TF, "2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation : executive summary", Thromb Haemost, 122, pp.20~47 (2022)
- Harrison SL, "Lipid levels, atrial fibrillation and the impact of age : results from the LIPIDOGRAM2015 study", Atherosclerosis, 312, pp.16~22 (2020)
- Emerging Risk Factors Collaboration, "Lipid-related markers and cardiovascular disease prediction", JAMA, 307, pp.2499~2506 (2012)
- Annoura M, "Cholesterol paradox in patients with paroxysmal atrial fibrillation", Cardiology, 92, pp.21~27 (1999)
- Guan B, "Blood lipid profiles and risk of atrial fibrillation : a systematic review and meta-analysis of cohort studies", J Clin Lipidol, 14, pp.133~142 (2020)
- Lee HJ, "Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation", J Am Heart Assoc, 8, pp.e012771~ (2019)
- Lopez FL, "Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation : the atherosclerosis risk in communities study", Circ Arrhythm Electrophysiol, 5, pp.155~162 (2012)
- Mora S, "Paradoxical association of lipoprotein measures with incident atrial fibrillation", Circ Arrhythm Electrophysiol, 7, pp.612~619 (2014)
- Collins R, "Interpretation of the evidence for the efficacy and safety of statin therapy", Lancet, 388, pp.2532~2561 (2016)
- Adhyaru BB, "Safety and efficacy of statin therapy", Nat Rev Cardiol, 15, pp.757~769 (2018)
- Fang WT, "The role of statin therapy in the prevention of atrial fibrillation : a meta-analysis of randomized controlled trials", Br J Clin Pharmacol, 74, pp.744~756 (2012)
- Chang CH, "Continuation of statin therapy and a decreased risk of atrial fibrillation", flutter in patients with and without chronic kidney disease, 2014, pp.232, 224~230
- Zhou X, "Statin therapy is beneficial for the prevention of atrial fibrillation in patients with coronary artery disease : a meta-analysis", Eur J Pharmacol, 707, pp.104~111 (2013)
- Corrado A, "Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials", J Atr Fibrillation, 1, pp.50~ (2008)
- Alonso A, "Blood lipids and the incidence of atrial fibrillation : the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study", J Am Heart Assoc, 3, pp.e001211~ (2014)
- Wong CX, "Epidemiology of atrial fibrillation : the Australian and Asia-Pacific perspective", Heart Lung Circ, 26, pp.870~879 (2017)
- Noubiap JJ, "A meta-analysis of clinical risk factors for stroke in anticoagulant-naïve patients with atrial fibrillation", Europace, 23, pp.1528~1538 (2021)
- Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- Seong SC, "Cohort profile : the National Health Insurance Service-National Health Screening Cohort(NHIS-HEALS)in Korea", BMJ Open, 7, pp.e016640~ (2017)
- Eue-Keun Choi, "Cardiovascular Research Using the Korean National Health Information Database", Korean Circulation Journal, 50(9), pp.754~772 (2020), 대한심장학회[DOI]
- Norby FL, "Association of lipid-related genetic variants with the incidence of atrial fibrillation : the AFGen consortium", PLoS One, 11, pp.e0151932~ (2016)
- Li X, "Lipid profile and incidence of atrial fibrillation : a prospective cohort study in China", Clin Cardiol, 41, pp.314~320 (2018)
- Peña JM, "High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation : an exploratory analysis of the JUPITER trial", Eur Heart J, 33, pp.531~537 (2012)
- Chugh SS, "Worldwide epidemiology of atrial fibrillation : a Global Burden of Disease 2010 Study", Circulation, 129, pp.837~847 (2014)
- ), "Am J Cardiol", 2018, 102~107
- Jacobs JM, "Cholesterol, statins, and longevity from age 70 to 90 years", J Am Med Dir Assoc, 14, pp.883~888 (2013)
- Tadic M, "What do we currently know about metabolic syndrome and atrial fibrillation?", Clin Cardiol, 36, pp.654~662 (2013)
- Abi-Char J, "Membrane cholesterol modulates Kv1. 5 potassium channel distribution and function in rat cardiomyocytes", J Physiol, 582, pp.1205~1217 (2007)
- Balse E, "Cholesterol modulates the recruitment of Kv1. 5 channels from Rab11-associated recycling endosome in native atrial myocytes", Proc Natl Acad Sci U S A, 106, pp.14681~14686 (2009)
- Khovidhunkit W, "Effects of infection and inflammation on lipid and lipoprotein metabolism : mechanisms and consequences to the host", J Lipid Res, 45, pp.1169~1196 (2004)
- Duntas LH, "Thyroid disease and lipids", Thyroid, 12, pp.287~293 (2002)
- Frost L, "Hyperthyroidism and risk of atrial fibrillation or flutter : a population-based study", Arch Intern Med, 164, pp.1675~1678 (2004)
- Heeringa J, "High-normal thyroid function and risk of atrial fibrillation : the Rotterdam study", Arch Intern Med, 168, pp.2219~2224 (2008)
- Guo Y, "Inflammation in atrial fibrillation", J Am Coll Cardiol, 60, pp.2263~2270 (2012)
- Tall AR, "Cholesterol, inflammation and innate immunity", Nat Rev Immunol, 15, pp.104~116 (2015)
- Xie W, "Mitochondrial oxidative stress promotes atrial fibrillation", Sci Rep, 5, pp.11427~ (2015)
- Fauchier L, "Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials", J Am Coll Cardiol, 51, pp.828~835 (2008)
- Haywood LJ, "Atrial fibrillation at baseline and during follow-up in ALLHAT(Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)", J Am Coll Cardiol, 54, pp.2023~2031 (2009)
- Liu T, "Statin use and development of atrial fibrillation : a systematic review and meta-analysis of randomized clinical trials and observational studies", Int J Cardiol, 126, pp.160~170 (2008)
- Young-Xu Y, "Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease", Am J Cardiol, 92, pp.1379~1383 (2003)
- Fauchier L, "Statin therapy and atrial fibrillation : systematic review and updated meta-analysis of published randomized controlled trials", Curr Opin Cardiol, pp.7~18 (2013)
- Li J, "Effects of rosuvastatin on serum asymmetric dimethylarginine levels and atrial structural remodeling in atrial fibrillation dogs", Pacing Clin Electrophysiol, 35, pp.456~464 (2012)